NCT05023928View on ClinicalTrials.gov

Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

October 1, 2023

Study Completion Date

October 30, 2024

Conditions
CarcinomaEsophagus Cancer
Interventions
BIOLOGICAL

Tumor antigen-sensitized DC vaccine

subcutaneous administration

Trial Locations (1)

610000

West China Hospital, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER

NCT05023928 - Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer | Biotech Hunter | Biotech Hunter